Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Summary

The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer. MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.

Timeline

Start

2010-07

Primary completion

2014-02

Completion

2014-02

Drugs

Indications